证券代码：688399 证券简称：硕世生物 公告编号：2025-035 江苏硕世生物科技股份有限公司 第三届监事会第十一次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日下午 14:00 以现场结合通讯方式召开第三届监事会第十一次会议（以下简称 "本次会议"）。本次会议通知于 2025 年 10 月 17 日向各位监事发出，本次会 议应到监事 3 人，实到监事 3 人。本次会议的召集、召开程序均符合《公司法》 《证券法》等法律、法规和规范性文件以及《公司章程》的规定。 会议由监事会主席马施达先生主持，经与会监事充分讨论，会议以记名投 票方式审议通过了如下议案： 一、审议通过《关于公司 2025 年第三季度报告的议案》 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露 的《江苏硕世生物科技股份有限公司关于 2025 年前三季度计提及转回资产减值 准备的公告》（公告编号：2025-036）。 表决结 ...

江苏硕世生物科技股份有限公司 2025 年第三季度报告 证券代码：688399 证券简称：硕世生物 江苏硕世生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 （二） 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 | 非经常性损益项目 | 本期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益，包括已计提 | -131,622.05 | 183,958.68 | | | 资产减值准备的冲销 ...

Core Viewpoint - The A-share market is experiencing a significant increase in cash dividends, with over 600 listed companies distributing more than 300 billion yuan in cash dividends for the first half of the year, indicating a shift towards a return-focused capital market [1][2]. Group 1: Dividend Distribution - As of October 24, over 30 A-share companies, including China Ping An and China Unicom, have completed their cash dividend distributions for the first half of 2025 [2]. - The total cash dividend amount for A-share companies reached 649.7 billion yuan, with a payout ratio of 31.97%, slightly up from the previous year [2][3]. - Central enterprises are leading the way in dividend distribution, with companies like China Mobile and China Petroleum distributing over 100 billion yuan each [2]. Group 2: Future Dividend Plans - More than 3 billion yuan in cash dividends are still pending distribution, with major banks and coal companies expected to contribute significantly [3]. - The third-quarter dividend window has opened, with over 30 companies planning to distribute more than 4 billion yuan in dividends [3]. - Companies are increasingly adopting a multi-dividend strategy, with firms like WuXi AppTec and CRRC announcing their first interim dividends this year [3]. Group 3: Dividend Yield and Investor Sentiment - The average dividend yield for companies that have distributed dividends is 2.52%, with over 90 companies yielding more than 3% [4]. - The proactive approach of companies in returning capital to shareholders has been recognized, with total distributions over the past five years reaching 10.6 trillion yuan, significantly higher than previous periods [4]. - Companies are making long-term commitments to shareholder returns, with some planning to distribute at least 70% of their net profits as dividends from 2025 to 2027 [4]. Group 4: Investment Perspective - The stable dividend distribution in the A-share market is attracting more attention to dividend assets, which are viewed as long-term investments rather than short-term speculative plays [5]. - Investors are encouraged to focus on the sustainability of dividend payments rather than short-term stock price fluctuations, reinforcing the long-term logic behind dividend investments [5].

Core Viewpoint - The Nasdaq China Golden Dragon Index experienced a significant drop of over 3%, marking the largest decline since August 27 [1] Company Performance - Kingsoft Cloud fell by 9% [1] - GDS Holdings, Daqo New Energy, and NIO all dropped by over 7% [1] - Upstart, JinkoSolar, Xiaopeng Motors, Zhihu, and WeRide saw declines of over 6% [1] - Bilibili, Alibaba, Baidu, and JD.com each fell by over 5% [1]

Core Viewpoint - Jiangsu Shuoshi Biotechnology Co., Ltd. has received a medical device registration certificate for in vitro diagnostic reagents, which is expected to enhance its product variety and competitive edge in the market [1]. Group 1: Medical Device Registration Certificate - The company has obtained a medical device registration certificate issued by the National Medical Products Administration for in vitro diagnostic reagents [1]. - This registration expands the company's product offerings and strengthens its presence in the in vitro diagnostics sector [1]. Group 2: Impact on the Company - The acquisition of the medical device registration certificate is anticipated to meet diverse clinical needs and enhance the company's overall competitiveness [1]. - It is expected to improve the company's market expansion capabilities [1].

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), has received medical device registration certificates from the National Medical Products Administration for two in vitro diagnostic products, enhancing its product offerings and competitive position in the market [1]. Product Development - The newly registered products include the Adenovirus Antigen Test Kit (Colloidal Gold Method) and the Nucleic Acid Test Kit for Seven Respiratory Pathogens (Fluorescent PCR Method) [1]. - The acquisition of these medical device registration certificates expands the company's product range in the in vitro diagnostic field [1]. Market Positioning - The introduction of these products aims to meet diverse clinical needs, thereby strengthening the company's overall competitiveness [1]. - This development is expected to improve the company's market expansion capabilities [1].

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), has received a medical device registration certificate from the National Medical Products Administration for two in vitro diagnostic products, enhancing its product offerings and competitive position in the market [1] Product Development - The newly registered products include the Adenovirus Antigen Test Kit (Colloidal Gold Method) and the Nucleic Acid Test Kit for Seven Respiratory Pathogens (Fluorescent PCR Method) [1] - The acquisition of these medical device registration certificates expands the company's portfolio in the in vitro diagnostic field [1] Market Positioning - The introduction of these products aims to meet diverse clinical needs, thereby strengthening the company's overall competitiveness [1] - This development is expected to enhance the company's market expansion capabilities [1]

Group 1 - The core point of the article is that Suosheng Biotechnology has received a medical device registration certificate from the National Medical Products Administration for products including the "Adenovirus Antigen Test Kit (Colloidal Gold Method)" [1] - For the fiscal year 2024, Suosheng Biotechnology's revenue composition is 94.78% from the in vitro diagnostic industry and 5.22% from other businesses [1] - As of the report, Suosheng Biotechnology has a market capitalization of 5.4 billion yuan [1] Group 2 - The article also highlights a competitive situation in the beverage industry, where Nongfu Spring's new green bottle product has led to a significant decline in market share for Yibao, dropping nearly 5 percentage points [1]

证券代码：688399 证券简称：硕世生物 公告编号：2025-034 江苏硕世生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局签发的医疗器械注册证（体外诊断试剂），具体信息如下： 序号 产品名称 注册编号 注册证 有效期 注册 分类 预期用途 1 腺病毒抗原检测试剂 盒（胶体金法） 国 械 注 准 20253401989 至 2030 年9月28 日 三类 本产品用于体外定性检 测人口咽拭子样本中的 腺病毒抗原。 2 七项呼吸道病原体核 酸检测试剂盒（荧光 PCR 法） 国 械 注 准 20253401991 至 2030 年9月28 日 三类 本试剂盒用于体外定性 检测人咽拭子样本中的 7 项呼吸道病原体核酸，包 括甲型流感病毒、乙型流 感病毒、呼吸道合胞病 毒、呼吸道腺病毒、副流 感病毒、鼻病毒和肺炎支 原体。检测结果可区分不 同病原体，但无法区分不 同型别。 一、医疗器械注册证的具 ...

Core Insights - The vitamin sector experienced a decline of 0.18% as of the market close on September 29, with *ST Suwu hitting the daily limit down, while stocks like Jilin Aodong, Keyuan Pharmaceutical, and Haixin Co. saw gains of 6.69%, 1.93%, and 1.83% respectively [1][2][3] Market Performance - The vitamin sector ranked among the top decliners, with significant losses observed in stocks such as *ST Suwu (-4.76%), Jincheng Pharmaceutical (-4.49%), and Huaheng Biological (-3.59%) [1][2] - Conversely, Jilin Aodong led the gains in the sector with a notable increase of 6.69%, followed by Keyuan Pharmaceutical and Haixin Co. [1][3] Capital Flow - The vitamin sector saw a net outflow of 374 million yuan, with 54 stocks experiencing net outflows, and 18 stocks seeing outflows exceeding 10 million yuan [1] - The stock with the highest net outflow was Angel Yeast, with 78.26 million yuan, followed by Jincheng Pharmaceutical and New Hecheng with outflows of 39.04 million yuan and 26.95 million yuan respectively [1][2] - In contrast, the stocks with the highest net inflows included Jilin Aodong (106 million yuan), Chuaning Biological (6.01 million yuan), and Shuoshi Biological (5.10 million yuan) [1][3]